Humanized mouse model reveals the immunogenicity of Hepatitis B Virus vaccine candidates produced in CRISPR/Cas9-edited Nicotiana benthamiana

Humanized mouse model reveals the immunogenicity of Hepatitis B Virus vaccine candidates produced in CRISPR/Cas9-edited Nicotiana benthamiana

IntroductionHepatitis B Virus (HBV) infection is still an ongoing public health issue worldwide. The most efficient tool in preventing HBV infection remains vaccination and significant efforts have been made in the last decade to improve current HBV vaccines. Owing to the strict HBV tropism for the...

Full description

Saved in:
Bibliographic Details
Main Authors: Iuliana Caras, Irina-Elena Ionescu, Ana-Maria Pantazica, André van Eerde, Hege Steen, Inger Heldal, Sissel Haugslien, Catalin Tucureanu, Raluca-Elena Chelmus, Vlad-Constantin Tofan, Adriana Costache, Adrian Onu, Hang Su, Norica Branza-Nichita, Jihong Liu-Clarke, Crina Stavaru
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
HBV
humanized mice
virus-neutralization
chimeric antigen
CRISPR/Cas9-edited Nicotiana benthamiana
immune response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1479689/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionHepatitis B Virus (HBV) infection is still an ongoing public health issue worldwide. The most efficient tool in preventing HBV infection remains vaccination and significant efforts have been made in the last decade to improve current HBV vaccines. Owing to the strict HBV tropism for the human liver, developing animal models for preclinical screening of vaccine candidates is extremely challenging. To date, there are only a few reports regarding the use of humanized mouse models for the evaluation of the immunogenic properties of viral antigens.MethodsPreviously we showed that a Nicotiana benthamiana-produced HBV-S/preS116-42 antigen elicited strong HBV-specific immune responses in BALB/c mice. In the current study, we used immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice as recipients of human peripheral blood mononuclear cells (hPBMCs), to evaluate the immunogenicity of the recently developed chimeric HBV immunogen produced in CRISPR/Cas9-edited N. benthamiana, under more “humanized” conditions.ResultsAnalysis of the immune response in NSG mice immunized with the chimeric antigen demonstrated induction of virus infection-neutralizing antibodies, indicating activation of antigen-specific B cells.DiscussionThe ability of hPBMCs-engrafted NSG mice to mount specific humoral immune responses after immunization with viral antigens supports this animal model as a promising tool for pre-clinical evaluation of human vaccine antigens.
ISSN:1664-3224

Similar Items